Research programme: combination therapies - TRINITY Laboratories

Drug Profile

Research programme: combination therapies - TRINITY Laboratories

Alternative Names: Dextromethorphan/gabapentin/tramadol; Dextromethorphan/sildenafil/tramadol; TLI 0651; TLI 1026

Latest Information Update: 23 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trinity Laboratories
  • Class Small molecules
  • Mechanism of Action NMDA receptor antagonists; Opioid mu receptor agonists; Serotonin uptake inhibitors; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dysmenorrhoea; Fibromyalgia; Neuropathic pain

Most Recent Events

  • 22 Jan 2016 TRINITY Laboratories has patent protection for TLI 1026 and treatment of premature ejaculation in USA
  • 22 Jan 2016 TRINITY laboratories plans a phase I trial for Dysmenorrhoea in USA (TRINITY website, January 2016)
  • 21 Jan 2016 Preclinical trials in Dysmenorrhoea in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top